Kelowna, BC – April 21, 2025 – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU7) (“Doseology” or the “Company”), an innovator in precision-formulated performance solutions, is providing a corporate update to its previously announced press release of March 4, 2025.

Due to recent market conditions, the Company is cancelling the two non-brokered strategic private placements. The Company confirms that no securities were issued in connection with these cancelled placements. The Company is currently reassessing the market as well as its strategic partnerships and will provide further updates shortly.

About Doseology Sciences Inc.

Doseology is a performance-driven innovation company at the intersection of biotechnology and advanced delivery systems, engineering precision-formulated oral stimulants that optimize energy, focus, and cognitive performance. Through science-backed research and cutting-edge formulation technologies, the Company is pioneering next-generation performance solutions that empower consumers to perform at their peak.

For more information, visit www.doseology.com

On Behalf of the Board of Directors

Dan Vice, Co-Founder Director
Doseology Sciences Inc.

Contact
📩hello@doseology.com

 

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions, and includes statements regarding the Company reassessing the market and its strategic partnerships and providing further updates shortly. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; the Company's ability to successfully complete its market reassessment and identify or secure strategic partnerships or alternative financing opportunities on favourable terms, or at all; potential delays or changes in the Company's strategic plans as a result of the reassessment; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s continuous disclosure documents filed on SEDAR+. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.